Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models

BACKGROUND: The development of secondary resistance (SR) in metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (anti-EGFR) antibodies is not fully understood at the molecular level. Here we tested in vivo selection of anti-EGFR SR tumors in CRC patient-derived xen...

Descripción completa

Detalles Bibliográficos
Autores principales: Vangala, Deepak, Ladigan, Swetlana, Liffers, Sven T., Noseir, Soha, Maghnouj, Abdelouahid, Götze, Tina-Maria, Verdoodt, Berlinda, Klein-Scory, Susanne, Godfrey, Laura, Zowada, Martina K., Huerta, Mario, Edelstein, Daniel L., de Villarreal, Jaime Martinez, Marqués, Miriam, Kumbrink, Jörg, Jung, Andreas, Schiergens, Tobias, Werner, Jens, Heinemann, Volker, Stintzing, Sebastian, Lindoerfer, Doris, Mansmann, Ulrich, Pohl, Michael, Teschendorf, Christian, Bernhardt, Christiane, Wolters, Heiner, Stern, Josef, Usta, Selami, Viebahn, Richard, Admard, Jacob, Casadei, Nicolas, Fröhling, Stefan, Ball, Claudia R., Siveke, Jens T., Glimm, Hanno, Tannapfel, Andrea, Schmiegel, Wolff, Hahn, Stephan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283888/
https://www.ncbi.nlm.nih.gov/pubmed/34271981
http://dx.doi.org/10.1186/s13073-021-00926-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283888/
https://www.ncbi.nlm.nih.gov/pubmed/34271981
http://dx.doi.org/10.1186/s13073-021-00926-7

Ejemplares similares